Persistent High Burden and Mortality Associated With Advanced HIV Disease in Rural Tanzania Despite Uptake of World Health Organization "Test and Treat" Guidelines.
advanced HIV disease
death and loss to follow-up
opportunistic infections
sub-Saharan Africa
test and treat
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
02
09
2022
accepted:
11
11
2022
entrez:
21
12
2022
pubmed:
22
12
2022
medline:
22
12
2022
Statut:
epublish
Résumé
Information about burden, characteristics, predictors, and outcomes of advanced human immunodeficiency virus disease (AHD) is scarce in rural settings of sub-Saharan Africa. Human immunodeficiency virus (HIV) infections and associated deaths remain high despite specific guidelines issued by the World Health Organization (WHO). Burden of AHD and 6-month death/loss to follow-up (LTFU) were described among 2498 antiretroviral therapy (ART)-naive nonpregnant people with HIV (PWH) aged >15 years enrolled in the Kilombero Ulanga Antiretroviral Cohort in rural Tanzania between 2013 and 2019. Baseline characteristics associated with AHD and predictors of death/LTFU among those with AHD were analyzed using multivariate logistic and Cox regression, respectively. Of the PWH, 62.2% had AHD at diagnosis (66.8% before vs 55.7% after national uptake of WHO "test and treat" guidelines in 2016). At baseline, older age, male sex, lower body mass index, elevated aminotransferase aspartate levels, severe anemia, tachycardia, decreased glomerular filtration rate, clinical complaints, impaired functional status, and enrollment into care before 2018 were independently associated with AHD. Among people with AHD, incidence of mortality, and LTFU were 16 and 34 per 100 person-years, respectively. WHO clinical stage 3 or 4, CD4 counts <100 cells/µL, severe anemia, tachypnea, and liver disease were associated with death/LTFU. More than 50% of PWH enrolled in our cohort after test and treat implementation still had AHD at diagnosis. Increasing HIV testing and uptake and implementation of the WHO-specific guidelines on AHD for prevention, diagnosis, treatment of opportunistic infections, and reducing the risks of LTFU are urgently needed to reduce morbidity and mortality.
Sections du résumé
Background
UNASSIGNED
Information about burden, characteristics, predictors, and outcomes of advanced human immunodeficiency virus disease (AHD) is scarce in rural settings of sub-Saharan Africa. Human immunodeficiency virus (HIV) infections and associated deaths remain high despite specific guidelines issued by the World Health Organization (WHO).
Methods
UNASSIGNED
Burden of AHD and 6-month death/loss to follow-up (LTFU) were described among 2498 antiretroviral therapy (ART)-naive nonpregnant people with HIV (PWH) aged >15 years enrolled in the Kilombero Ulanga Antiretroviral Cohort in rural Tanzania between 2013 and 2019. Baseline characteristics associated with AHD and predictors of death/LTFU among those with AHD were analyzed using multivariate logistic and Cox regression, respectively.
Results
UNASSIGNED
Of the PWH, 62.2% had AHD at diagnosis (66.8% before vs 55.7% after national uptake of WHO "test and treat" guidelines in 2016). At baseline, older age, male sex, lower body mass index, elevated aminotransferase aspartate levels, severe anemia, tachycardia, decreased glomerular filtration rate, clinical complaints, impaired functional status, and enrollment into care before 2018 were independently associated with AHD. Among people with AHD, incidence of mortality, and LTFU were 16 and 34 per 100 person-years, respectively. WHO clinical stage 3 or 4, CD4 counts <100 cells/µL, severe anemia, tachypnea, and liver disease were associated with death/LTFU.
Conclusions
UNASSIGNED
More than 50% of PWH enrolled in our cohort after test and treat implementation still had AHD at diagnosis. Increasing HIV testing and uptake and implementation of the WHO-specific guidelines on AHD for prevention, diagnosis, treatment of opportunistic infections, and reducing the risks of LTFU are urgently needed to reduce morbidity and mortality.
Identifiants
pubmed: 36540386
doi: 10.1093/ofid/ofac611
pii: ofac611
pmc: PMC9757676
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofac611Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
N Engl J Med. 2017 Jul 20;377(3):233-245
pubmed: 28723333
Curr Opin HIV AIDS. 2017 Mar;12(2):123-128
pubmed: 28059957
AIDS. 2017 Oct 23;31(16):2217-2225
pubmed: 28742529
HIV Med. 2012 Oct;13(9):541-8
pubmed: 22416813
Glob Health Action. 2019;12(1):1679472
pubmed: 31679482
Clin Infect Dis. 2004 May 15;38(10):1454-63
pubmed: 15156485
Open Forum Infect Dis. 2017 Jul 23;4(3):ofx156
pubmed: 28959700
Am J Epidemiol. 2021 Feb 1;190(2):251-264
pubmed: 33524120
BMC Infect Dis. 2022 Jan 6;22(1):37
pubmed: 34991496
PLoS Med. 2013;10(9):e1001510
pubmed: 24137103
AIDS Educ Prev. 2009 Jun;21(3 Suppl):106-21
pubmed: 19537958
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S111-S117
pubmed: 29514238
Swiss Med Wkly. 2017 Jul 11;147:w14485
pubmed: 28695551
HIV Med. 2004 Mar;5(2):93-8
pubmed: 15012648
PLoS One. 2020 Jan 7;15(1):e0226987
pubmed: 31910221
J Int AIDS Soc. 2018 Dec;21(12):e25210
pubmed: 30549245
Clin Infect Dis. 2015 Apr 1;60(7):1120-7
pubmed: 25516189
J Int Assoc Provid AIDS Care. 2015 Mar-Apr;14(2):148-55
pubmed: 23792708
PLoS One. 2009 Jun 04;4(6):e5790
pubmed: 19495419
J Sex Transm Dis. 2017;2017:7075601
pubmed: 28702270
Clin Infect Dis. 2016 Jun 15;62(12):1595-1603
pubmed: 26951573
Malawi Med J. 2015 Dec;27(4):125-7
pubmed: 26952140
Clin Infect Dis. 2014 Feb;58(3):432-41
pubmed: 24198226
Clin Infect Dis. 2021 Dec 15;73(Suppl_5):S343-S350
pubmed: 34910173
Trop Med Int Health. 2017 Apr;22(4):375-387
pubmed: 28102610
AIDS Res Hum Retroviruses. 2020 Jan;36(1):39-47
pubmed: 31359762
Medicine (Baltimore). 2018 Apr;97(16):e0380
pubmed: 29668591
PLoS One. 2011;6(12):e28691
pubmed: 22220193
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219847199
pubmed: 31104543
BMC Infect Dis. 2019 Mar 15;19(1):261
pubmed: 30876400
PLoS One. 2017 Jul 18;12(7):e0180983
pubmed: 28719610
PLoS One. 2019 Apr 10;14(4):e0214739
pubmed: 30969987
Can J Infect Dis Med Microbiol. 2018 Jul 04;2018:1346104
pubmed: 30073038
Lancet Infect Dis. 2017 Aug;17(8):873-881
pubmed: 28483415
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S140-S146
pubmed: 29514235
J Int AIDS Soc. 2020 Mar;23(3):e25458
pubmed: 32128964
Clin Infect Dis. 2018 Mar 5;66(6):893-903
pubmed: 29373672
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126